These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
611 related articles for article (PubMed ID: 22733540)
1. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540 [TBL] [Abstract][Full Text] [Related]
2. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells. Musi E; Ambrosini G; de Stanchina E; Schwartz GK Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540 [TBL] [Abstract][Full Text] [Related]
3. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163 [TBL] [Abstract][Full Text] [Related]
4. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786 [TBL] [Abstract][Full Text] [Related]
5. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib. Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284 [TBL] [Abstract][Full Text] [Related]
6. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Ambrosini G; Musi E; Ho AL; de Stanchina E; Schwartz GK Mol Cancer Ther; 2013 May; 12(5):768-76. PubMed ID: 23443802 [TBL] [Abstract][Full Text] [Related]
8. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748 [TBL] [Abstract][Full Text] [Related]
9. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Cheng H; Chua V; Liao C; Purwin TJ; Terai M; Kageyama K; Davies MA; Sato T; Aplin AE Mol Cancer Ther; 2017 Mar; 16(3):516-528. PubMed ID: 28138035 [TBL] [Abstract][Full Text] [Related]
10. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations. Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078 [TBL] [Abstract][Full Text] [Related]
12. Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation. Cerne JZ; Hartig SM; Hamilton MP; Chew SA; Mitsiades N; Poulaki V; McGuire SE Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2130-9. PubMed ID: 24595385 [TBL] [Abstract][Full Text] [Related]
13. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways. Wu X; Li J; Zhu M; Fletcher JA; Hodi FS Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968 [TBL] [Abstract][Full Text] [Related]